Medifast Reports Q3 2026 Revenue of $72.05 Million, Sets Q4 Guidance
Revenue fell 19.4% year over year but exceeded analyst consensus of $71.3 million. Medifast reported a GAAP loss of $1.57 per share and set Q4 2026 revenue and GAAP EPS guidance midpoints of $65 million and $0.13. Full-year EBITDA guidance has a $12 million midpoint, above analyst consensus of $4.4 million.
Medifast, Inc. reported third quarter 2026 revenue of $72.05 million, representing a 19.4% year-over-year decline, though the figure exceeded analyst consensus estimates of $71.3 million. The company recorded a GAAP loss of $1.57 per share, which was significantly below analyst expectations. Management provided guidance for the fourth quarter of 2026, projecting revenue at a midpoint of $65 million and GAAP EPS at a midpoint of $0.13.
Additionally, the company set its full-year EBITDA guidance at a midpoint of $12 million, which is above the analyst consensus of $4.4 million. The company's operating margin for the quarter was -26.9%, compared to -4.6% in the same period last year.